Update on the Treatment of Metastatic Urothelial Carcinoma

Table 1

Treatment options for metastatic urothelial carcinoma [10].

First-line cisplatin eligible	Cis/Gem, MVAC.
First-line cisplatin ineligible	Chemotherapy: Carbo/Gem, single agent chemotherapy.
	Immunotherapy: Atezolizumab or Pembrolizumab.
	Clinical trial
Second line	Immunotherapy: Pembrolizumab, Atezolizumab, Nivolumab, Durvalumab and Avelumab.
	Chemotherapy: single agent Vinflunine, Taxanes (Paclitaxel, nab-paclitaxel and Docetaxel), Gemcitabine, Pemetrexed.
	Clinical trial